AI Consensus Investment Thesis
Akeso (9926) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
BUYHK$105
+16.0%5-Year
BUYHK$179
+97.6%Latest flagship insight
Bispecific Clinical Superiority Meets Unforgiving Western Valuation Realities
A dense consensus reveals sharp divergence between undeniable clinical survival data and aggressive equity valuations. While domestic reimbursement volume drives self-funding commercial scale, long-duration multiples face severe headwinds from partner royalty limitations, multinational bispecific competition, and restrictive sovereign discount rates.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Machiavelli (Insider), Superintelligence (Anthropologist), Elon Musk (Visionary), Michael Burry (Vulture), Sherlock Holmes (Whistleblower), Universal Investor (Polymath), J.P. Morgan (Titan), Warren Buffett (Value Purist), Ray Dalio (Strategist). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Akeso at the forecast anchor (2026-09-18): $19,889 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in HKD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (HKD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 94.50 | +4.42% | +4.42% | Regulatory scrutiny surrounding initial Western filings creates volatility, but expanding fourth-quarter domestic hospital shipments under comprehensive national reimbursement listings cushion overall sentiment and reinforce baseline operational progress. |
| Q1 2027 | 97.55 | +3.23% | +7.79% | Full-year results confirm commercial sales growth exceeding twenty-five percent and narrowing operational losses, though elevated global discount rates and trial cash burn cap speculative valuation multiple expansion. |
| Q2 2027 | 101.99 | +4.55% | +12.70% | Oncology congress disclosures highlight robust survival data across secondary solid tumor indications, prompting tactical accumulation while investors await definitive multiregional clinical trial updates from overseas partners. |
| Q3 2027 | 105.02 | +2.97% | +16.04% | Interim financial reporting confirms steady hospital volume ramp, but tightening monetary conditions and digestion of foreign clinical data prompt moderate profit-taking across long-duration healthcare holdings. |
| Q4 2027 | 110.16 | +4.89% | +21.72% | Domestic reimbursement renewal adjustments impose expected price concessions on earlier indications, yet overall prescription elasticity and early milestone receipts preserve top-line momentum and stabilize gross profit generation. |
| Q1 2028 | 113.79 | +3.30% | +25.74% | Annual disclosures indicate the domestic business is approaching cash-flow breakeven as manufacturing economies of scale dilute fixed costs, reducing perceived balance sheet vulnerability among institutional allocators. |
| Q2 2028 | 119.66 | +5.16% | +32.22% | Pivotal multiregional Phase III survival data readouts demonstrate solid efficacy in broader patient cohorts, partially de-risking Western commercialization and triggering contractually guaranteed partner milestone inflows. |
| Q3 2028 | 124.22 | +3.81% | +37.26% | Global regulatory filings advance smoothly, but competitive clinical updates from multinational pharmaceutical fast-followers temper long-term terminal pricing assumptions and induce disciplined equity price consolidation. |
| Q4 2028 | 131.33 | +5.72% | +45.11% | Western regulatory progress triggers initial licensing milestone revenues, while domestic label expansions across gastrointestinal cancers widen patient volume, supporting fundamental valuation progression into fiscal year-end. |
| Q1 2029 | 136.07 | +3.61% | +50.35% | Audited results confirm inaugural corporate operating breakeven, marking a pivotal transition from developmental cash burn toward self-funding commercial viability across core Asian oncology franchises. |
| Q2 2029 | 139.85 | +2.78% | +54.53% | Commercial preparation for Western product rollouts progresses, alongside advancing clinical trials for next-generation bispecific antibody-drug conjugates that replenish the firm's long-term organic development pipeline. |
| Q3 2029 | 144.05 | +3.00% | +59.17% | Initial Western commercial shipments begin yielding recurring low-double-digit royalty flows, which provide pure-margin cash accretion that counters ongoing clinical research expenditures. |
| Q4 2029 | 150.07 | +4.18% | +65.82% | Routine reimbursement renegotiations in China moderate unit realizations, but high hospital penetration and expanding patient cohorts maintain consolidated revenue compounding and preserve operating profitability. |
| Q1 2030 | 154.94 | +3.25% | +71.21% | Annual financial reporting demonstrates positive net earnings and expanding free cash flow, encouraging long-only institutional accumulation as multiple discovery shifts toward price-to-earnings metrics. |
| Q2 2030 | 160.37 | +3.50% | +77.20% | Secondary indication approvals in major international jurisdictions broaden the global addressable patient population, supporting royalty remittance compounding despite encroaching biosimilar competition. |
| Q3 2030 | 161.25 | +0.55% | +78.18% | Maturing oncology indications experience modest market share stabilization, prompting brief valuation consolidation while the market evaluates clinical trial progress in non-oncology autoimmune pipelines. |
| Q4 2030 | 166.25 | +3.10% | +83.70% | Sustained global royalty collections and disciplined factory capacity utilization deliver consistent cash generation, prompting management to evaluate initial shareholder capital return frameworks. |
| Q1 2031 | 170.72 | +2.69% | +88.64% | Full-year reporting validates durable double-digit operating margins, confirming that high-margin overseas royalties successfully complement high-volume domestic sales to sustain institutional earnings quality. |
| Q2 2031 | 174.72 | +2.34% | +93.06% | Next-generation antibody-drug conjugates enter late-stage registrational studies, sustaining platform innovation premiums while established bispecific franchises generate predictable recurring commercial cash flows. |
| Q3 2031 | 178.80 | +2.34% | +97.57% | The five-year scenario concludes with the business firmly established as an integrated, cash-generative biopharmaceutical enterprise trading at a normalized through-cycle earnings valuation. |
The investment thesis hinges on separating Akeso's verified domestic commercial inflection from the speculative capitalization of its overseas royalty rights. Domestically, twelve indications listed on the National Reimbursement Drug List drive commercial sales growth near thirty percent, successfully absorbing fixed clinical infrastructure and narrowing operating deficits toward breakeven. However, market pricing frequently conflates Summit Therapeutics' prospective gross product revenues with Akeso's contractual low-double-digit royalty entitlement. Against five-percent sovereign benchmark yields and strict foreign regulatory scrutiny, the firm's rich price-to-sales multiple faces persistent gravitational drag, requiring realized operational cash flows rather than clinical narratives to support valuation.
Key insights
- Contractual licensing structures cap Akeso's foreign economic capture at modest royalties, shifting execution burdens to partners while restricting unencumbered equity upside.
- Reimbursement-driven domestic volume growth overcomes statutory price discounts, establishing a self-sustaining operational baseline independent of Western regulatory timing or geopolitical frictionsgeopolitical frictionsInternational tensions that disrupt trade routes and supply chain stability for global hardware manufacturers.View full glossary entry.
- Competing multiregional bispecific and antibody-drug conjugate pipelines from well-capitalized multinational pharmaceutical peers threaten to compress the first-mover commercial exclusivity window.
Akeso is transforming from an expensive research laboratory into a profitable pharmaceutical company. Sales of its cancer drugs in Chinese hospitals are surging rapidly, which helps cover heavy trial costs and moves the business close to breakeven. However, investors who expect instant global riches overlook that overseas sales belong mostly to a foreign partner, with Akeso collecting only a modest royalty fee. With high interest rates punishing speculative stocks, sustainable share gains require real corporate profits rather than scientific excitement.
Key insights
- Surging hospital sales in China provide a reliable financial foundation that protects the core business.
- Foreign sales generate high-margin royalty checks without clinical trial costs, but dollar amounts remain limited.
- Global drug giants are advancing rival treatments, which could shorten the time Akeso dominates the market.
Deep Dive
The prevailing consensus treats ivonescimab's survival victory over standard checkpoint inhibitors as a guaranteed global blockbuster annuity, pricing frictionless Western commercialization. Sell-side analysts anchor heavily on aggressive peak sales projections, assuming regulatory agencies will rapidly clear Chinese-origin clinical data while largely ignoring domestic reimbursement price renegotiations and persistent operational cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? The prevailing consensus treats ivonescimab's survival victory over standard checkpoint inhibitors as a guaranteed global blockbuster annuity, pricing frictionless Western commercialization. Sell-side analysts anchor heavily on aggressive peak sales projections, assuming regulatory agencies will rapidly clear Chinese-origin clinical data while largely ignoring domestic reimbursement price renegotiations and persistent operational cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates the standalone profitability of Akeso's domestic commercial engine while overestimating near-term Western cash velocity. The critical analytical edge lies in recognizing that Akeso captures only a low-double-digit royalty on overseas sales, not gross revenues. However, twelve domestic reimbursement listings provide an underappreciated, self-funding commercial fortress that insulates corporate solvency even if foreign regulatory milestones face delays.
Repricing Catalyst
What could make the market recognize and close that gap? The primary convergence catalyst is the sequence of global Phase III multiregional clinical trial readouts, alongside upcoming Western regulatory filing reviews. Statistically robust survival confirmation across non-Asian patient cohorts will force institutional allocators to replace speculative pipeline multiples with tangible forward royalty cash-flow models, narrowing the equity risk premium.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Balanced
- Volatility
- High Erratic
- Cycle position
- Growing Awareness
Sentiment is split between retail clinical enthusiasm and institutional valuation caution. Observers debate whether recent survival trial triumphs justify premium sales multiples, or whether high discount rates and interim trial variability dictate near-term multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of restrictive central bank interest rates and elevated sovereign yields represents a persistent valuation headwind for long-duration biotechnology assets. This setup enforces multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry on speculative earnings, although Akeso's liquid reserves exceeding nine billion renminbi completely insulate its clinical pipeline from debt refinancingdebt refinancingReplacing existing debt with new borrowing, often to change maturity, interest cost, currency, or covenants.View full glossary entry distress.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive disagreement centers on whether Akeso's valuation should reflect an emerging global pharmaceutical titan or a domestic commercial innovator. Optimistic models assume seamless Western regulatory approvals, projecting multi-billion-dollar royalty windfalls that justify premium sales multiples. Contrarian perspectives emphasize that Akeso captured only a royalty slice rather than gross Western revenues, while highlighting interim trial variance, aggressive Chinese reimbursement price cuts, and the valuation drag of elevated discount rates. Reconciling this debate requires observing whether multiregional survival trials replicate domestic efficacy and whether domestic volume expansion delivers positive operating cash flowoperating cash flowCash generated or consumed by a company's core business operations.View full glossary entry by 2028.
Base-Case Forces
Event Risk ScoreHigh64/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Reimbursement volume accelerates domestic adoption | Competitive Positioning | +36% | +55% | Integration of twelve core indications across five commercial products into China's National Reimbursement Drug List unlocks rapid hospital penetration. Expanding prescription volumes across thoracic and gynecological oncology compensate for negotiated unit price concessions, delivering sustained product sales growth above twenty-five percent and systematically absorbing manufacturing overhead. |
| Partner licensing generates high-margin royalties | Capital Allocation | +28% | +45% | The out-licensing agreement with Summit Therapeutics externalizes the substantial capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry of multiregional Western trials. Impending regulatory milestones and low-double-digit royalties on ex-China commercial sales provide zero-marginal-cost cash inflows that drop directly to net operating income, accelerating corporate progression toward cash self-sufficiency. |
| Proven clinical survival superiority moat | Innovation And Product | +24% | +35% | Head-to-head clinical trials establishing statistically significant progression-free and overall survival advantages over standard-of-care monotherapies dismantle conventional oncology regimens. Therapeutic differentiation in first-line lung and gastrointestinal cancers secures physician prescribing loyalty, defending premium formulary positioning and expanding the long-term addressable patient population. |
| Biomanufacturing scale expands operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry | Operational Efficiency | +18% | +30% | In-house large-scale biomanufacturing facilities in southern China generate substantial unit cost advantages over outsourced models. As commercial production scales, fixed operating expenses amortize over expanding volume, defending gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry near eighty percent and driving corporate operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry across the breakeven threshold into sustainable profitability. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Monetary tightening compresses long-duration multiples | Macroeconomic And Macrofinancial | -20% | -8.0% | Persistent central bank policy tightening and benchmark sovereign yields near five percent elevate corporate capital costs. Higher discount rates severely penalize long-duration biotechnology valuation multiples, forcing equity pricing to anchor strictly on realized operating cash flows rather than distant projected pipeline royalty streams. |
| National reimbursement mandatory price clawbacks | Regulatory | -16% | -25% | Periodic centralized procurement renegotiations by China's National Healthcare Security Administration enforce recurring price concessions on mature indications. These administrative price reductions cap unit revenue realizations, requiring continuous volume expansion across hospital networks simply to preserve baseline gross profit contributions over time. |
| Fast-follower bispecific and ADC crowding | Competitive Positioning | -14% | -18% | Global pharmaceutical giants and agile domestic biopharma competitors are rapidly mobilizing competing dual-targeting antibodies and antibody-drug conjugate regimens. This encroaching competitive pipeline threatens to shorten Akeso's clinical exclusivity window, compress terminal market share, and escalate detailing expenditures in crowded frontline oncology indications. |
| Persistent multiregional clinical trial burn | Operational Efficiency | -12% | -20% | Sustaining dozens of concurrent global and domestic registrational clinical trials consumes substantial research capital, exceeding CNY 1.5 billion annually. Heavy clinical trial expenditures maintain headline operating losses and defer corporate free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry inflection until commercial revenues achieve critical mass. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Multiregional trial survival replication failure | 31% | -42% | Pivotal multiregional Phase III trials could fail to replicate China's remarkable survival superiority in Western demographic cohorts due to biological variance or standard-of-care differences. This event carries a thirty-one percent probability and would dismantle foreign licensing expectations, triggering severe multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry and stranding the firm within domestic markets. |
| Geopolitical biosecurity cross-border licensing sanctions | 22% | -38% | Escalating cross-border geopolitical frictiongeopolitical frictionExternal political tensions impacting global trade and operational stability for international companies.View full glossary entry could culminate in targeted legislative measures restricting biotechnology collaboration or royalty repatriations from Chinese clinical intellectual propertyintellectual propertyLegally protected intangible creations such as patents, copyrights, trademarks, designs, trade secrets, and proprietary know-how.View full glossary entry. Carrying a twenty-two percent probability, this risk would disrupt Western distribution channels, halt overseas clinical operations, and impose a permanent geopolitical riskgeopolitical riskThe potential for political instability or international tensions to negatively impact business operations and valuation.View full glossary entry discount on the equity. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Accelerated Western regulatory approval milestone | 32% | +45% | Foreign regulatory agencies could grant priority review or accelerated approval for ivonescimab based on mature multiregional clinical subsets. This outcome carries a thirty-two percent probability due to strict foreign trial scrutiny, but it would pull forward hundreds of millions in development milestones and activate lucrative Western royalties years ahead of schedule. |
| Multinational licensing of secondary pipeline | 24% | +38% | A tier-one global pharmaceutical company facing patent-cliff exposure could acquire exclusive international rights to Akeso's bispecific antibody-drug conjugate or autoimmune candidates. Triggered by breakthrough Phase II solid tumor data, a major deal carries a twenty-four percent probability and would deliver substantial upfront cash, permanently removing external financing risks. |
Company Financial Analysis
Akeso Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Akeso's financial performance highlights a company rapidly transitioning from heavy clinical spending to commercial self-sufficiency. Commercial drug sales expanded 51.5% in fiscal 2025 to RMB 3.03 billion, with momentum continuing into the first half of 2026 as product revenue rose 28.7% to RMB 1.80 billion. Net operating losses contracted from RMB 918 million in 2025 to RMB 418 million in interim 2026, confirming that rising prescription sales are beginning to outrun baseline overhead costs. This trend demonstrates that hospital prescription demand is driving the business rather than one-time licensing fees. As manufacturing scale improves and overseas royalties begin flowing in, fixed expenses will be diluted further, paving a realistic path toward full operational profitability.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | CNY 3B | CNY -1.1B | CNY -1.8B |
| 2024 | HKD 2.1B | HKD -514.5M | HKD -1.1B |
| 2023 | HKD 4.5B | HKD 2B | CNY 1.6B |
| 2022 | CNY 837.7M | CNY -1.2B | CNY -2B |
| 2021 | CNY 225.6M | CNY -1.1B | CNY -1.7B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | HKD / -- |
| 2024 | 30.6x | TTM | USD-normalized | HKD / -- |
| 2023 | -- | TTM | Unavailable | HKD / -- |
| 2022 | -- | Annual | Loss-making | HKD / CNY |
| 2021 | -- | Annual | Loss-making | HKD / CNY |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Akeso's margins reveal strong underlying manufacturing economics alongside classic biotechnology growth dynamics. Gross profit margins printed at a robust 78.7% in 2025, supported by proprietary biologic production efficiencies despite government reimbursement price discounts. Operating margins remained negative at -30.8% due to active research trials, but narrowed dramatically from negative 160% in 2022. This steady improvement demonstrates powerful operating leverage overcoming statutory price cuts. Because future overseas royalty payments carry virtually zero manufacturing costs, high gross margins will directly lift the bottom line as global sales materialize, driving sustained profit margin expansion.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | CNY -918.2M | -30.8% | -36.4% |
| 2024 | HKD -570.4M | -26.9% | -24.2% |
| 2023 | HKD 2B | 45.2% | 44.8% |
| 2022 | CNY -1.3B | -160.0% | -139.5% |
| 2021 | CNY -1.2B | -553.0% | -476.4% |
Balance sheet and leverage
AI Review
Akeso maintains exceptional financial strength that insulates the business from credit market volatility. As of mid-2026, liquid cash and short-term financial assets stood at RMB 9.16 billion, substantially exceeding total obligations. A conservative debt-to-equity ratio of 0.50 and a current ratio of 5.14 demonstrate that short-term solvency risk is essentially nonexistent. This large cash cushion gives management strategic independence, providing multiple years of operational runway without the need for dilutive share sales or expensive debt. It ensures that planned clinical pipelines can be funded internally while commercial sales scale toward self-sufficiency.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | CNY 4.6B | CNY 9.2B | CNY 4.3B net cash | 5.14x |
| 2024 | CNY 4B | CNY 7.3B | CNY 2.9B net cash | 5.15x |
| 2023 | CNY 3B | CNY 4.9B | CNY 1.1B net cash | 4.71x |
| 2022 | CNY 1.9B | CNY 2.3B | CNY 213.3M net cash | 2.25x |
| 2021 | CNY 859.4M | CNY 2.6B | CNY 1.8B net cash | 4.81x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management's spending shows disciplined capital allocation following an aggressive phase of factory construction. Capital expenditures dropped from over ninety percent of revenue in 2022 to 23.9% in 2025 as major manufacturing facilities were completed. Meanwhile, research and development spending remained focused at CNY 1.53 billion in 2025 and CNY 773 million in the first half of 2026, advancing core late-stage clinical programs. This shift from physical construction to clinical development preserves capital while ensuring ample factory capacity to supply expanding hospital sales. By partnering with external developers to fund expensive Western trials, Akeso protects its cash reserves while maintaining high-margin participation in global drug sales.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | CNY 712.1M | CNY 1.5B |
| 2024 | HKD 585.8M | HKD 1.2B |
| 2023 | CNY 879.5M | HKD 1.3B |
| 2022 | CNY 775.6M | CNY 1.3B |
| 2021 | CNY 712.1M | CNY 1.1B |
Quarterly Forecast Scenarios
Akeso Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in HKD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (HKD) | Base case (HKD) | Bull case (HKD) | S&P 500 benchmark (USD) | FX (USD/HKD) |
|---|---|---|---|---|---|
| HK$86.88 | HK$94.70 | HK$103.17 | $750.26 | 7.8388 | |
| HK$82.54 | HK$98.88 | HK$111.42 | $736.44 | 7.8051 | |
| HK$84.19 | HK$104.64 | HK$124.79 | $743.40 | 7.7827 | |
| HK$81.66 | HK$107.69 | HK$142.09 | $755.15 | 7.7993 | |
| HK$82.48 | HK$114.72 | HK$161.98 | $776.22 | 7.8160 | |
| HK$85.78 | HK$120.03 | HK$168.46 | $787.13 | 7.8215 | |
| HK$91.78 | HK$127.56 | HK$183.62 | $802.83 | 7.8213 | |
| HK$95.61 | HK$131.71 | HK$205.66 | $812.05 | 7.8212 | |
| HK$99.26 | HK$141.58 | HK$236.51 | $839.18 | 7.8155 | |
| HK$101.42 | HK$149.53 | HK$262.52 | $850.50 | 7.8099 | |
| HK$104.46 | HK$156.39 | HK$280.90 | $872.39 | 7.7930 | |
| HK$102.37 | HK$160.62 | HK$303.37 | $885.51 | 7.8041 | |
| HK$106.47 | HK$168.54 | HK$321.57 | $909.56 | 7.8096 | |
| HK$108.60 | HK$176.44 | HK$347.30 | $916.13 | 7.8151 | |
| HK$111.85 | HK$183.07 | HK$357.72 | $936.51 | 7.8150 | |
| HK$112.97 | HK$185.09 | HK$382.76 | $947.34 | 7.7982 | |
| HK$116.36 | HK$191.93 | HK$398.07 | $969.59 | 7.7981 | |
| HK$118.69 | HK$198.87 | HK$417.97 | $979.99 | 7.7981 | |
| HK$119.88 | HK$204.17 | HK$434.69 | $999.60 | 7.7981 | |
| HK$122.27 | HK$209.06 | HK$447.73 | $1,012 | 7.7981 |
Behind the synthesis
How each opinion shapes the consensus
The consensus centers on an independently supported operational reality: commercial domestic revenues are rapidly expanding across twelve reimbursed oncology indications, narrowing operating losses while backed by a solid liquid cushion of over nine billion renminbi. However, substantial divergence emerges concerning the valuation of offshore assets. Highly weighted reports rigorously document that Western rights were out-licensed for low-double-digit royalties rather than gross product sales, while identifying material clinical hurdles including interim progression-free survival setbacks and intense competition from multinational bispecific programs. Conversely, heavily downweighted reports assume frictionless global monopoly substitution, aggressive multiple expansion, and immediate thirty-five percent operating margins without evidentiary support. Under current high global hurdle rates, unearned foreign royalties cannot justify speculative sales multiples. The chosen weighting balances proven domestic volume-driven operating leverage against realistic Western regulatory timelines and persistent clinical reinvestment demands.
Universal Investor AI
The Polymath
Opus 5Provides exceptional empirical grounding with primary clinical and corporate disclosures. Correctly separates domestic commercial earnings from external royalty optionality while accounting for interim trial hiccups and emerging competitive bispecific pipelines from global pharmaceutical incumbents.
Universal Investor AI
The Polymath
GPT-6 AstraDisplays disciplined financial forensic rigor, properly distinguishing product revenues from partner royalty streams and identifying mixed-currency reporting discrepancies. Sets a defensible valuation framework anchored in conservative penetration rates and elevated discount rates.
Michael Burry AI
The Vulture
Gemini 3.8 FlashProvides a crucial contrarian corrective to market euphoria. Highlights persistent clinical trial cash burn, mandatory reimbursement price clawbacks, and discount rate sensitivity, successfully grounding valuation in realistic near-term operating cash flows.
Elon Musk AI
The Visionary
Gemini 3.8 FlashPresents a vital economic reality check: Akeso captured only a royalty slice rather than gross Western product revenues. Correctly models multiple compression from rich starting valuations while acknowledging genuine bispecific clinical differentiation.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashDemonstrates thorough verification of domestic revenue expansion and reimbursement listing, but relies on somewhat optimistic assumptions regarding Western regulatory speed and operating margin conversion without fully incorporating competitor clinical pipeline entries.
Universal Investor AI
The Polymath
Gemini 3.8 FlashOffers sound balance sheet evaluation and realistic capex intensity trends, but relies on a standard multiple expansion narrative that underweights the structural discount rate pressure facing long-duration biotechnology equities.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashContributes strong forensic analysis of narrowing interim losses and commercial hospital volume growth, but slightly minimizes the probability of Western regulatory delay and demographic cohort scrutiny by foreign agencies.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashSynthesizes macro debt and liquidity dynamics with healthcare demand elasticity well, though its long-term compounding path slightly underweights fast-follower pipeline threats across major epithelial solid tumors.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashAccurately highlights domestic institutional alignment and state health procurement incentives, though it slightly overstates the speed of Western royalty monetization and discounts protectionist geopolitical friction in developed markets.
Universal Investor AI
The Polymath
Gemini 3.8 FlashConstructive synthesis of dual-engine commercialization and balance sheet reserves, but exhibits moderate correlation with earlier reports and leans heavily on aggressive multiple expansion amidst restrictive monetary policy.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashThoughtful biological framing and platform analysis, but relies on speculative international milestone timelines and assigns insufficient probability to domestic procurement price erosion across mature antibody indications.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashExtremely bullish scenario projects quadrupling equity value based on speculative monopoly pricing. Lacks independent source grounding, neglects regulatory trial risks, and assumes unrealistic clinical displacement speed across global oncology markets.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashValidates ongoing capital consumption and multiple contraction risks, yet understates the resilience of liquid cash reserves and the immediate volume contribution from newly listed national reimbursement indications.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashContains excessive optimism regarding operating margins expanding above 35% without sufficient evidence. Overlooks persistent trial expenditures and the economic reality of low-double-digit royalty limits on overseas product commercialization.
Research Provenance
References & Context
This Akeso consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 79 deduplicated sources retained for this batch.
- 01a2026_prx0129xfdablaaccesec.gov
- 02https://www.sec.gov/Archives/edgar/data/1599298/000159929826000067/a20260723q2earningsdeck_.htm?utm_source=openaisec.gov
- 03smmt-20250331sec.gov
- 04smmt-20251231sec.gov
- 05Akeso, Inc | Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer'sakesobio.com
- 06Akeso, Inc | Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer'sakesobio.com
- 07康方生物 - Akeso, Inc | 依沃西对比帕博利珠单抗一线治疗PD-L1阳性NSCLC（HARMONi-2研究）OS统计学显著阳性结果在WCLC 2026重磅发布akesobio.com
- 08康方生物 - Akeso, Inc | 公司新闻akesobio.com
- 09Summit shares descend as PD-1/VEGF asset misses early survival mark - BioSpacebiospace.com
- 10Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients - BioSpacebiospace.com
- 11AACR: Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plansfiercebiotech.com
- 12With Summit leading the pack in PD-1xVEGF bispecifics, Pfizer lays out its own plan to replace Keytruda | Fierce Biotechfiercebiotech.com
- 13Summit Therapeutics updates ivonescimab survival data ahead of FDA decision datefiercepharma.com
- 14Summit's PD-1xVEGF interim trial miss surprises analysts, shares tumblefiercepharma.com
- 15Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in Chinafinance.yahoo.com
And 64 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
4 fieldscapitalExpenditures · freeCashFlow · salePurchaseOfStock · totalCashFromOperatingActivities
annual: 2018-12-31–2025-12-31, 8 periods; quarterly: 2023-12-31–2026-06-30, 6 periods
Currencies cited: CNY, HKD, USD (quote HKD; primary reporting CNY; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.